244 related articles for article (PubMed ID: 30020745)
21. Adherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis.
Li P; Blum MA; Von Feldt J; Hennessy S; Doshi JA
Value Health; 2010; 13(6):805-12. PubMed ID: 21054657
[TBL] [Abstract][Full Text] [Related]
22. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
[TBL] [Abstract][Full Text] [Related]
23. Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis.
Curtis JR; Schabert VF; Yeaw J; Korn JR; Quach C; Harrison DJ; Yun H; Joseph GJ; Collier D
J Med Econ; 2014 Aug; 17(8):555-66. PubMed ID: 24754646
[TBL] [Abstract][Full Text] [Related]
24. Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: An analysis of the South Korean National Health Insurance Database.
Lee MY; Shin JY; Park SY; Kim D; Cha HS; Lee EK
Semin Arthritis Rheum; 2018 Feb; 47(4):485-491. PubMed ID: 28939234
[TBL] [Abstract][Full Text] [Related]
25. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
26. Health Care Resource Utilization and Costs Associated With Switching Biologics in Rheumatoid Arthritis.
Vanderpoel J; Tkacz J; Brady BL; Ellis L
Clin Ther; 2019 Jun; 41(6):1080-1089.e5. PubMed ID: 31122662
[TBL] [Abstract][Full Text] [Related]
27. Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis.
Grabner M; Boytsov NN; Huang Q; Zhang X; Yan T; Curtis JR
Arthritis Res Ther; 2017 May; 19(1):92. PubMed ID: 28506320
[TBL] [Abstract][Full Text] [Related]
28. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
Wong BJ; Cifaldi MA; Roy S; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
[TBL] [Abstract][Full Text] [Related]
29. Treatment patterns and annual drug costs of biologic therapies across indications from the Humana commercial database.
Howe A; Eyck LT; Dufour R; Shah N; Harrison DJ
J Manag Care Spec Pharm; 2014 Dec; 20(12):1236-44. PubMed ID: 25443517
[TBL] [Abstract][Full Text] [Related]
30. Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses from an Administrative Claims Database.
Walsh JA; Adejoro O; Chastek B; Palmer JB; Hur P
J Manag Care Spec Pharm; 2018 Jul; 24(7):623-631. PubMed ID: 29952704
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database.
Harnett J; Gerber R; Gruben D; Koenig AS; Chen C
J Manag Care Spec Pharm; 2016 Dec; 22(12):1457-1471. PubMed ID: 27882833
[TBL] [Abstract][Full Text] [Related]
32. Impact of Switching From an Initial Tumor Necrosis Factor Inhibitor on Health Care Resource Utilization and Costs Among Patients With Rheumatoid Arthritis.
Baser O; Ganguli A; Roy S; Xie L; Cifaldi M
Clin Ther; 2015 Jul; 37(7):1454-65. PubMed ID: 25999184
[TBL] [Abstract][Full Text] [Related]
33. Healthcare resource utilization and costs among patients with rheumatoid arthritis on biologic therapies in Taiwan: A 1-year mirror-image study using a national claims database.
Chen KC; Wu CH; Tang CH; Huang KC
PLoS One; 2018; 13(7):e0200758. PubMed ID: 30020997
[TBL] [Abstract][Full Text] [Related]
34. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach.
Cimmino MA; Leardini G; Salaffi F; Intorcia M; Bellatreccia A; Dupont D; Beresniak A
Clin Exp Rheumatol; 2011; 29(4):633-41. PubMed ID: 21813056
[TBL] [Abstract][Full Text] [Related]
35. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
[TBL] [Abstract][Full Text] [Related]
36. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
Tang B; Rahman M; Waters HC; Callegari P
Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998
[TBL] [Abstract][Full Text] [Related]
37. Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-α Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study.
Dalén J; Luttropp K; Svedbom A; Black CM; Kachroo S
Adv Ther; 2020 Sep; 37(9):3746-3760. PubMed ID: 32647910
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world.
Yang M; Galebach PJ; Signorovitch JE; Garg V
Clin Exp Rheumatol; 2017; 35(5):791-798. PubMed ID: 28339358
[TBL] [Abstract][Full Text] [Related]
39. Assessing the Association of Formulary Copayment Changes with Real-World Treatment Patterns in Patients with Rheumatoid Arthritis on Etanercept.
Bonafede M; Oko-Osi H; Gharaibeh M; Manjelievskaia J; Lopez-Gonzalez L; Collier DH; Stolshek BS
J Manag Care Spec Pharm; 2020 Feb; 26(2):211-220. PubMed ID: 31823689
[TBL] [Abstract][Full Text] [Related]
40. Comparing biologic persistence and healthcare costs in rheumatoid arthritis patients initiating subcutaneous biologics.
Nadkarni A; McMorrow D; Fowler R; Smith D
J Comp Eff Res; 2017 Nov; 6(8):659-669. PubMed ID: 28791873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
